Autologous Transplantation of Expanded Pancreatic Islet Cells (YD01-2022) in Patients

Diabetes After Total Pancreatectomy Clinical Trial

Official title:
Evaluation of the Efficacy and Safety of Autologous Transplantation of Expanded Pancreatic Islet Cells (YD01-2022) in Patients With Diabetes Mellitus After Total Pancreatectomy

Status Recruiting

Clinical Trial Summary

This study will evaluate the efficacy and safety of autologous transplantation of expanded pancreatic islet cells in patients with diabetes mellitus after total pancreatectomy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Diabetes After Total Pancreatectomy

Clinical Trial Details

NCT number	NCT05990517
Study type	Interventional
Source	Shanghai Jiao Tong University School of Medicine
Contact	Weiqiong Gu, PhD
Phone	86-21-64370045
Email	Gwq10978@rjh.com.cn
Status	Recruiting
Phase	Phase 2
Start date	February 22, 2023
Completion date	August 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04064203` - The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)	N/A
Completed	`NCT02640118` - The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects	N/A
Enrolling by invitation	`NCT02944110` - Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism	N/A
Completed	`NCT04061473` - Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion	N/A